A Phase 3 interventional study of Escitalopram and Aripiprazole in Major Depressive Disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 60 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-26.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies testing escitalopram in Depressive Disorder, Major — 7 open to participants now, 8 under way, 1 of them phase 3. Escitalopram · Depressive Disorder, Major.
Among the 100 studies testing escitalopram in Depressive Disorder, Major, this one is the 28th largest by enrollment of the 99 interventional ones that give a count, is one of 9 that started in 2010, is one of 18 in phase 3, and was the 50th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →7 of the 100 studies testing escitalopram in Depressive Disorder, Major are open now, in 10 countries. Recruiting first, the newest first:
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
Medical University of Vienna · Sites in Austria
Ages 18–65 · Healthy volunteers
Peking University · Sites in China
Ages 18–55
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19–65
By country, each count listing its studies:
Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 21 · Phase 4 53
First in 2002; this study’s year is marked. 9 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 237 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 80 across the 99 interventional studies. Of the 75 that completed or were terminated, 41 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 100 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 23rd largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2010, is one of 23 in phase 3, and was the 9th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
4 of the studies testing escitalopram in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06675851Medical University of ViennaReward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People | 2026-12 |
| NCT05004987NYU Langone HealthAβ Dynamics in LLMD | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
| NCT07478796Poznan University of Medical SciencesTDM-Guided Treatment With SSRIs in Hospitalized Adults and Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 100 studies testing escitalopram in Depressive Disorder, Major, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an incomplete response to a prospective trial of Escitalopram, and report a treatment history for the current MDD episode of an inadequate response to at least one and no more than three adequate trials of an approved antidepressant other than Escitalopram. An inadequate response is defined as less than a 50% reduction in depressive symptom severity as assessed by the participant's self-report on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and evaluated by the investigator as part of the participant's medical and psychiatric history. An adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for combination treatments) at an approved dose as specified in the ATRQ.
The study will be organized as follows:
Assigned Interventions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the end of Week 1 based upon tolerability profile, plus one matching placebo capsule, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
Drug: Escitalopram · Drug: Placebo
Participants with response at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B plus one matching placebo capsule, for an additional 6 weeks, in Phase B+.
Drug: Escitalopram · Drug: Placebo
Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
Drug: Escitalopram · Drug: Placebo
Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any week, based upon tolerability.
Drug: Aripiprazole · Drug: Placebo
Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.
Drug: Escitalopram · Drug: Aripiprazole · Drug: Placebo
Escitalopram oral capsules.
Aripiprazole oral capsules.
Also known as: OPC-14597
Study drug matching placebo capsule.
Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14)
The MADRS assessed severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms). Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). A negative change from Week 8 indicates improvement. Last observation carried forward (LOCF) method was used for analyses.
Time frame: Week 8 to Week 14
Phase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at The End of Phase C (Week 14)
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. Last observation carried forward (LOCF) method was used for analyses.
Time frame: Week 14
Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14)
The SDS is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0= no impairment to 10= most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe). A negative change from Week 8 indicates improvement. Last observation carried forward (LOCF) method was used for analyses.
Time frame: Week 8 to Week 14
Participants took part in the study at 69 investigative sites in Australia, Bulgaria, India, Philippines, Romania, Russia, Slovakia, and the United States from 29 July 2010 to 27 September 2011.
| Milestone | Phase B: Single-blind Prospective Treatment Phase | Phase B+: Single-blind Phase B Responders | Phase C: Escitalopram Monotherapy | Phase C: Aripiprazole Monotherapy | Phase C: Aripiprazole/Escitalopram Combination Therapy |
|---|---|---|---|---|---|
| Started | 237 | 0 | 0 | 0 | 0 |
| Completed | 120 | 0 | 0 | 0 | 0 |
| Not completed | 117 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor discontinued study | 89 | 0 | 0 | 0 | 0 |
| Withdrew: Participant met withdrawal criteria | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator withdrew participant | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Participant withdrew consent | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy as determined by investigator | 1 | 0 | 0 | 0 | 0 |
| Milestone | Phase B: Single-blind Prospective Treatment Phase | Phase B+: Single-blind Phase B Responders | Phase C: Escitalopram Monotherapy | Phase C: Aripiprazole Monotherapy | Phase C: Aripiprazole/Escitalopram Combination Therapy |
|---|---|---|---|---|---|
| Started | 0 | 54 | 22 | 21 | 23 |
| Completed | 0 | 45 | 17 | 17 | 18 |
| Not completed | 0 | 9 | 5 | 4 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor discontinued study | 0 | 5 | 4 | 3 | 5 |
| Withdrew: Participant met withdrawal criteria | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Investigator withdrew participant | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant withdrew consent | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 | 0 |
The MADRS assessed severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms). Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). A negative change from Week 8 indicates improvement. Last observation carried forward (LOCF) method was used for analyses.
| score on a scale | Phase C: Escitalopram Monotherapy | Phase C: Aripiprazole Monotherapy | Phase C: Aripiprazole/Escitalopram Combination Therapy |
|---|---|---|---|
| Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14) | -8.0 ± 1.7 | -9.6 ± 1.7 | -9.2 ± 1.6 |
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. Last observation carried forward (LOCF) method was used for analyses.
| score on a scale | Phase C: Escitalopram Monotherapy | Phase C: Aripiprazole Monotherapy | Phase C: Aripiprazole/Escitalopram Combination Therapy |
|---|---|---|---|
| Phase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at The End of Phase C (Week 14) | 2.4 ± 0.3 | 2.3 ± 0.2 | 2.3 ± 0.2 |
The SDS is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0= no impairment to 10= most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe). A negative change from Week 8 indicates improvement. Last observation carried forward (LOCF) method was used for analyses.
| score on a scale | Phase C: Escitalopram Monotherapy | Phase C: Aripiprazole Monotherapy | Phase C: Aripiprazole/Escitalopram Combination Therapy |
|---|---|---|---|
| Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14) | -0.9 ± 0.5 | -1.4 ± 0.5 | -1.2 ± 0.5 |
Collected over From first dose of study drug through end of study (up to 22 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase B: Single-blind Prospective Treatment Phase | 0/237 (0%) | 2/237 (0.8%) | 53/237 (22.4%) |
| Phase B+: Single-blind Phase B Responders | 0/54 (0%) | 1/54 (1.9%) | 7/54 (13%) |
| Phase C: Escitalopram Monotherapy | 0/22 (0%) | 1/22 (4.5%) | 5/22 (22.7%) |
| Phase C: Aripiprazole Monotherapy | 0/21 (0%) | 0/21 (0%) | 10/21 (47.6%) |
| Phase C: Aripiprazole/Escitalopram Combination Therapy | 0/23 (0%) | 0/23 (0%) | 11/23 (47.8%) |
| Event | Phase B: Single-blind Prospective Treatment Phase | Phase B+: Single-blind Phase B Responders | Phase C: Escitalopram Monotherapy | Phase C: Aripiprazole Monotherapy | Phase C: Aripiprazole/Escitalopram Combination Therapy |
|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/237 | 0/54 | 1/22 | 0/21 | 0/23 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/237 | 1/54 | 0/22 | 0/21 | 0/23 |
| DepressionPsychiatric disorders | 1/237 | 0/54 | 0/22 | 0/21 | 0/23 |
| Physical assaultSocial circumstances | 1/237 | 0/54 | 0/22 | 0/21 | 0/23 |
| Event | Phase B: Single-blind Prospective Treatment Phase | Phase B+: Single-blind Phase B Responders | Phase C: Escitalopram Monotherapy | Phase C: Aripiprazole Monotherapy | Phase C: Aripiprazole/Escitalopram Combination Therapy |
|---|---|---|---|---|---|
| DizzinessNervous system disorders | 8/237 | 0/54 | 1/22 | 4/21 | 1/23 |
| DiarrhoeaGastrointestinal disorders | 10/237 | 2/54 | 0/22 | 3/21 | 0/23 |
| Upper Respiratory Tract InfectionInfections and infestations | 5/237 | 1/54 | 0/22 | 2/21 | 2/23 |
| AkathisiaNervous system disorders | 0/237 | 0/54 | 0/22 | 2/21 | 2/23 |
| NauseaGastrointestinal disorders | 18/237 | 0/54 | 2/22 | 1/21 | 1/23 |
| ConstipationGastrointestinal disorders | 1/237 | 0/54 | 2/22 | 0/21 | 1/23 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/237 | 0/54 | 2/22 | 0/21 | 1/23 |
| Weight increasedInvestigations | 2/237 | 2/54 | 0/22 | 0/21 | 2/23 |
| HeadacheNervous system disorders | 20/237 | 2/54 | 1/22 | 0/21 | 2/23 |
| RestlessnessPsychiatric disorders | 0/237 | 0/54 | 0/22 | 1/21 | 2/23 |
Phase B Sample included all participants who took at least one dose of escitalopram as indicated on the dosing record.
| Age, Continuous(years) | Phase B: Single-blind Prospective Treatment Phase |
|---|---|
| Mean | 45.2 ± 11.3 |
| Sex: Female, Male(Participants) | Phase B: Single-blind Prospective Treatment Phase |
|---|---|
| Female | 156 |
| Male | 81 |
| Ethnicity (NIH/OMB)(Participants) | Phase B: Single-blind Prospective Treatment Phase |
|---|---|
| Hispanic or Latino | 18 |
| Not Hispanic or Latino | 218 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Phase B: Single-blind Prospective Treatment Phase |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 15 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 30 |
| White | 186 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
No publications or documents are linked to this record.
Ran from Jul 2010 to primary completion in Sep 2011, 13 months.
Results were first posted in Oct 2021, 10 years after primary completion. A results delay was requested in Aug 2012.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Escitalopram · Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →